Choriocarcinoma is a malignant neoplasia which develops from trophoblastic cells. In males it is rare and often associated with other non-seminomatous germ cell tumours of the testis. Choriocarcinoma often presents with metastatic disease and elevated βHCG levels.
Many studies have highlighted that elevated body mass index (BMI) not only correlates with an elevated likelihood of developing breast cancer (BC) but may also influence patients’ responsiveness to therapeutic regimens and long-term survival outcomes. The impact of BMI on therapeutic response to neoadjuvant chemotherapy (NAC) in patients with BC remains inconclusive. This study seeks to evaluate the effect of BMI on treatment response in the BC population undergoing NAC via a meta-analysis, thereby providing evidence-based support for clinical decision-making.
Our study evaluated the desire to procreate of 96 mothers of children treated for cancer at the Pediatric Oncology Unit of Istituto Nazionale Tumori of Milan in 2021. Even at a time during which they fear losing the child they already have, nearly one in four mothers expressed their desire to have another child.
As a serious malignancy of the head and neck region, laryngeal cancer (LC) exhibits active glycolysis that produces lactate, a metabolite capable of inducing protein lactylation. However, the role of lactate-induced modifications in LC progression remains poorly understood. Although ALYREF has been identified as an oncogenic driver in several cancers, its function in LC has not yet been investigated.
Cachexia is a multifactorial syndrome prevalent in advanced illness. Guidelines rarely integrate the relational, multidimensional perspective of palliative care (PC). Addressing this gap is essential to optimize care. To achieve this, national consensus among PC physicians and nurses on principles and priorities for managing cachexia within PC settings is necessary.
Selpercatinib and pralsetinib are targeted therapies for non-small cell lung cancer. However, their adverse reaction profiles remain incompletely understood. This study aims to evaluate the post-marketing adverse events (AEs) associated with selpercatinib and pralsetinib in real-world populations.
The digitalization of clinical research has increased reliance on electronic portals (e-portals), with significant implications for trial site operations. Our aim is to map the types and number of e-portals required for clinical trials on solid tumors conducted at the Niguarda Cancer Center.
We performed an aggregated analysis of 65 interventional drug trials (phase I–III) initiated between August 2022 and March 2025. For each study, the number and type of e-portals required at the site were recorded and stratified by sponsor type. Analyses were conducted using R.
Read the latest issue. It contains the following articles:
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives
Delphi Study on the creation of a Committee of patients, caregivers, and representatives of patient associations
The e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations
An indirect approach to identify the healthcare services for thyroid and melanoma cancer patients in Italy: Epicost-2 project
Association of APOC1 levels and nutritional indices with clinicopathological features and prognostic value in patients with DLBCL
Predicting severe toxicity after head-and-neck cancer RT: Validation of the synergist role of a biological marker and dosimetry
Effects of uniportal 3D video-assisted thoracic surgery lobectomy on postoperative pain and immune function in patients with NSCLC
Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis
Medical decision analysis is a method to make rational clinical decisions under uncertainty, enabling a mathematical combination of probabilities and utilities (i.e. values assigned to outcomes under risk). Decision analysis is commonly used in health economics, but it is underexploited in the clinic.
This study aimed to systematically analyze the incidence, mortality, and risk factors of hematologic malignancies and their subtypes in China from 1990-2021.
The study utilized data from the Global Burden of Disease 2021 database. Trends in incidence and mortality rates of hematologic malignancies from 1990-2021 were measured using estimated annual percentage change (EAPC) with 95% confidence intervals. Future burden in China up to 2035 was projected using Bayesian age-period-cohort modeling.